scispace - formally typeset
Open AccessJournal ArticleDOI

Differential regulation of proinflammatory mediators following LPS- and ATP-induced activation of monocytes from patients with antiphospholipid syndrome.

Reads0
Chats0
TLDR
Increased sensitivity of APS cells to LPS that may contribute to thrombus formation and enhance development or progression of autoimmune processes is indicated.
Abstract
Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by recurrent thrombosis and pregnancy morbidity in association with the presence of antiphospholipid antibodies. Growing evidence supports the involvement of monocytes in APS pathogenesis. Inflammatory activation of monocytes promotes thrombus formation and other APS complications. However, mechanisms underlying their activation are poorly investigated. We aimed to determine transcriptional activity of monocytes after exposing them to low concentrations of lipopolysaccharide (LPS) and LPS + adenosine triphosphate (ATP) using comparative qRT-PCR. The results showed that LPS significantly increased transcriptional levels of TLR2, IL-23, CCL2, CXCL10, IL-1β, and IL-6 in APS cells, while, in cells from healthy donors, LPS resulted in IL-6 and STAT3 elevated mRNAs. Double stimulation of the cells resulted in decreased mRNA levels of NLRP3 in monocytes isolated from healthy donors and CCL2, IL-1β in APS cells. By contrast, TLR2 mRNAs were elevated in both investigated groups after culture of the cells with LPS + ATP. Thus, the findings indicate increased sensitivity of APS cells to LPS that may contribute to thrombus formation and enhance development or progression of autoimmune processes. Low concentrations of ATP diminish LPS-induced inflammatory state of APS monocytes which might be a potential mechanism which regulates inflammatory state of the cells.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Delineating the deranged immune system in the antiphospholipid syndrome

TL;DR: A plea is made for future extensive immune cell profiling by a systems medicine approach in order to better unravel the pathogenesis of APS to gain more insight in the role of the immune system in APS as well as having the potential to reveal biomarkers or novel therapeutic targets.
Journal ArticleDOI

Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.

TL;DR: This review summarizes and critically assess the pathogenic and non-pathogenic formation of aPLs and its contribution to the development of APS.
Journal ArticleDOI

Electronegative LDL induces priming and inflammasome activation leading to IL-1β release in human monocytes and macrophages

TL;DR: LDL(−) promotes release of biologically active IL-1β in monocytes and MDM by induction of the two steps involved: priming and NLRP3 inflammasome activation.
Journal ArticleDOI

Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response.

TL;DR: The results suggest that arterial hypertension and monocyte counts may be independent factors for thrombosis recurrence in APS, and may support the evaluation of therapeutic measures to a rigid control of blood pressures and modulation of inflammatory response in APs, as additional prophylaxis against the recurrence of vascular events.
References
More filters
Journal ArticleDOI

P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation.

TL;DR: The purinergic signalling system is bound to yield novel therapeutic opportunities for the treatment of inflammatory diseases because it is comprised of extracellular ATP, P2 receptors and ecto-enzyme cascades.
Journal Article

ATP induces the release of IL-1 from LPS-primed cells in vivo.

TL;DR: Adenosine 5'-O-(3-thiotriphosphate) was also effective in causing IL-1 release but not UTP or ADP, suggesting that the ATP-mediated release of IL- 1 is a receptor-mediated phenomenon that is associated with cell lysis.
Journal ArticleDOI

Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice.

TL;DR: It is shown that the development of a full-blown antibody-dependent autoimmune disease requires C5a--produced by and acting on FcgammaR--and may suggest therapeutic benefits of C5 and/or C5 a/C5aR blockade in AIHA and other diseases closely related to type II autoimmune injury.
Journal ArticleDOI

IL-10 expression profiling in human monocytes.

TL;DR: Analysis of the regulation of eight of these genes showed a remarkable specificity to regulation by lipopolysaccharides (LPS) and IL‐10, but not by other anti‐inflammatory mediators such as IL‐4 and transforming growth factor‐β, suggesting that two diverse stimuli such asIL‐10 and LPS may engage common signaling mechanisms.
Related Papers (5)